/

LYEL

Lyell Immunopharma, Inc.After hours

7.51−0.76 −9.19%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delayAfter hours 7.55 +0.53%

Open

8.27

Prev close

8.27

Day range

7.398.27

52-week range

7.3945.00

Volume

187.17K1.29×

Mkt cap

184.03M

P/E ttm

—

Fwd P/E

-1.19

EPS ttm

-12.86

Div yield

0.00%

Earnings

—

From 52w high

−83.31%

Price Chart

Yahoo Finance · delayed

LYELOct 13, 2026O 8.27H 8.27L 7.39C 7.51−0.76 (−9.19%)Vol 187.17K

SMA 5012.30
SMA 20018.06

1Y change −54.51% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

LYEL Lyell Immunopharma, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −12.78%
1 month: −37.21%
3 months: −43.96%
6 months: −67.86%
Year to date: −75.60%
1 year: −55.38%

Valuation & ownership

Market cap: 184.03M
Enterprise value: 45.15M
P/E (ttm): —
Forward P/E: -1.19
PEG ratio: —
Price / book: 0.75
Price / sales (ttm): 6816.06
EV / EBITDA: -0.25
EPS (ttm): -12.86
EPS (forward): -6.32
Beta (5y monthly): -0.03
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 24.51M
Float: 12.13M
Short % of float: 6.02%
Short ratio (days): 9.40
Held by insiders: 37.31%
Held by institutions: 54.22%
Avg volume (3m): 145.04K
50-day average: 12.41
200-day average: 18.21
52-week change: −55.38%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): oversold 18.4
vs 50-day SMA: −38.94%
vs 200-day SMA: −58.41%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 8.64%
Realised vol (20d, ann.): 48.7%
From 52-week high: −83.31%
From 52-week low: +1.62%

ANR

Analyst Consensus

8 analysts

Consensus

—

Mean target

37.88

+404.33% implied

Low 12.00Median 41.50High 49.00

Recommendation trend

Now7 / 0 / 1
1m ago7 / 0 / 1

DES

About Lyell Immunopharma, Inc.

Yahoo Finance profile

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 161
Headquarters: South San Francisco, CA, United States
Website: lyell.com
Officers

SEAS

Seasonality · LYEL

2021–2026 · monthly returns

Strongest month Feb +18.32%Weakest month Mar −17.11%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-22.0	0.0	-16.4	-1.6	-12.2	-18.9	-7.9	10.7	-31.6	-23.3			−75.6%
2025	-7.8	20.5	-24.3	-11.7	-8.0	1.1	33.6	-6.2	46.6	2.6	44.1	28.3	+140.5%
2024	-5.7	59.6	-23.6	-2.7	27.6	-47.7	11.0	-9.9	-4.8	-30.4	-1.6	-32.3	−67.0%
2023	-5.8	-34.3	9.8	-14.0	57.1	-0.3	-9.1	-17.3	-38.5	12.6	4.5	12.1	−44.1%
2022	-26.6	27.5	-30.2	1.6	-19.3	57.5	-14.6	20.3	9.4	-19.8	-28.4	-17.6	−55.2%
2021							-10.7	8.9	-6.3	-5.8	-31.5	-19.0	−52.3%

INSD

Insider Activity · LYEL

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 9, 2026	Shook David M.D.Officer	Sale at price 12.70 per share.	500	$6.35K
Aug 20, 2026	Seely LynnChief Executive Officer	Sale at price 15.54 per share.	9.6K	$149.01K
Aug 20, 2026	Hill Stephen JChief Operating Officer	Sale at price 15.54 per share.	989	$15.37K
Aug 20, 2026	Lee Gary KOfficer	Sale at price 15.54 per share.	1.5K	$22.64K
Aug 9, 2026	Seely LynnChief Executive Officer	Sale at price 14.34 per share.	390	$5.59K
Aug 9, 2026	Hill Stephen JChief Operating Officer	Sale at price 14.34 per share.	89	$1.28K
Aug 9, 2026	Lee Gary KOfficer	Sale at price 14.34 per share.	131	$1.88K
Aug 9, 2026	Bulis Veronica SanchezOfficer	Sale at price 14.34 per share.	621	$8.90K
Jul 16, 2026	Innovative Cellular Therapeutics Holdings LtdBeneficial Owner of more than 10% of a Class of Security	Sale at price 13.70 per share.	10	$137
Jul 15, 2026	Innovative Cellular Therapeutics Holdings LtdBeneficial Owner of more than 10% of a Class of Security	Sale at price 13.73 per share.	10	$137
Jun 9, 2026	Shook David M.D.Officer	Sale at price 12.64 per share.	2K	$24.99K
May 10, 2026	Seely LynnChief Executive Officer	Sale at price 18.91 per share.	388	$7.34K
May 10, 2026	Hill Stephen JChief Operating Officer	Sale at price 18.92 per share.	89	$1.68K
May 10, 2026	Lee Gary KOfficer	Sale at price 18.92 per share.	130	$2.46K
May 10, 2026	Bulis Veronica SanchezOfficer	Sale at price 18.91 per share.	217	$4.10K
Mar 5, 2026	Arch Venture Partners Ix,L.L.C.Beneficial Owner of more than 10% of a Class of Security	Purchase at price 25.61 per share.	488.1K	$12.50M
Mar 5, 2026	Arch Venture Fund Xiii, L..PBeneficial Owner of more than 10% of a Class of Security	Purchase at price 25.61 per share.	488.1K	$12.50M
Feb 10, 2026	Seely LynnChief Executive Officer	Sale at price 23.39 per share.	7.5K	$174.37K
Feb 10, 2026	Hill Stephen JChief Operating Officer	Sale at price 23.39 per share.	1.2K	$28.91K
Feb 10, 2026	Lee Gary KOfficer	Sale at price 23.39 per share.	1.7K	$39.09K

13F

Investors Holding LYEL

latest 13F filings of 29 followed managers

Investors holding LYEL
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$1.8M	0.00%	130.19K	+12%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

LYEL

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

LYEL

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Lyell Immunopharma, Inc.

Seasonality · LYEL

Insider Activity · LYEL

Congress Trades · LYEL

Investors Holding LYEL

Investors Holding LYEL

Congress Trades · LYEL

Insider Activity · LYEL

Seasonality · LYEL

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Lyell Immunopharma, Inc.

Financial Snapshot

Earnings & Dividends

News